Subject index to volume 120

SUBJECT INDEX TO VOLUME 120 Abac:avir, GI toxicity and GI-associated drug interactions of, 120:607 ABT 378, GI toxicity and GI-associated drug interactions of, 120:607 Ac:halasia, diagnosis of, esophageal manometry for, 120:783-tmig, 120: 789

Ac:quired immunodeficiency syndrome (AIDS). See HIV-infected (AIDS) patients; Human immunodeficiency virus (HIV-l) Activation protein I (AP·I), and butyric acid-induced apoptosis in colon cancer cells, 120:71 Adaptive cytoprotection, in gastric mucosa, PGI 2 and CGRP in, 120:134

Ad.efovir dipivoxil GI toxicity and GI-associated drug interactions of, 120:607 therapy with, for hepatitis B, 120:1828srr

Adenomas characteristics of, and risk of recurrence, 120:1071-tmig, 120:1077 colonic exophytic, aberrant expression of G 1phase cell cycle regulators in, 120:1680 flat, aberrant expression of G I-phase cell cycle regulators in, 120: 1680 colorectal, flat, prevalence and biologic features of, in North American population, 120:1657 Agenerase. See Amprenavir Alc:ohol. See Ethanol Alc:oholic: steatosis, Kupffer cell in (rat), 120:581-ss

Alosetron adverse effects and side effects of, 120: 557-cr, 120:652 ischemic colitis caused by, 120:557-cr therapy with, in irritable bowel syndrome, 120:652 Alport syndrome, pathology of, 120: 216-cr Alternative medicine, in treatment of irritable bowel syndrome, 120: 652

Americ:an Gastroenterologic:al Association

Antimitoc:hondrial antiBody, in

and HCFA policy effects on gastroenterologists and Medicare patients, 120:3-gn medical position statement on celiac sprue, 120:1522 on guidelines for evaluation of food allergies, 120:1023 on nausea and vomiting, 120:261 new president-Jon 1. Isenberg, M.D., 120:1518 goals of, 120:786-gn presentation of the Julius M. Friedenwald Medal to Don W. Powell, M.D., 120:1854 technical review on celiac sprue, 120:1526 on evaluation of food allergy in gastrointestinal disorders, 120: 1026 on nausea and vomiting, 120:263 Amprenavir, GI toxicity and GI-associated drug interactions of, 120: 607 Anal c:anal, cancer of, risk of, HPV and, 120:784-tmig, 120:857, 120: 1046-e Anal fistula, in Crohn's disease, initial medical management for, costutility of, 120: 1640 Anemia, duodenal expression of stimulator of Fe transport and transferrin receptor in, 120:1404 Angiodysplasia, bleeding, of gastrointestinal tract, abnormal von Willebrand factor in, 120:346

Antineutrophil cytoplasmic: antibody (ANCA), and LTA hap-

Antic:oagulant therapy for mesenteric vein thrombosis, 120: 578-ss for portal vein thrombosis, 120:490, 120:578-ss Antidepressants, in treatment of irritable bowel syndrome, 120:652 Antidiarrheal agents, in treatment of irritable bowel syndrome, 120: 652 Antiemetic: agents, for nausea and vomiting, 120:263-aga

KEY TO ABBREVIATIONS

aga-American Gastroenterological Association pmr-Print and Media Reviews c-Correspondence rc-Rapid Communications ce-Comment From the Editors ss-Selected Summaries cr-Case Reports srr-Special Reports and Reviews gn-Gastroenterology News tmig-This Month in Gastroenterology e-Editorials vidd-Viewpoints in Digestive im-Image of the Month

liver disease, 120:239-srr

lotype, and responses to infliximab in Crohn's disease, 120: 1347 Antinuc:lear antibodies, in liver disease, 120:239-srr Antiretroviral therapy, for HIV-l infection adverse effects and side effects of, 120: 607 efficacy of, 120:607 Antisense IeAM-I, in treatment of chronic active Crohn's disease, 120:1317-tmig, 120:1339 APe gene, Il307K mutation, and increased risk of transition from polyp to colorectal carcinoma in Ashkenazi Jews, 120:331-tmig, 120:392

Apoptosis buryric acid-induced, JNKJAPI pathway in, 120:71 of CD8+ T cells, in liver, 120:250-srr in colon cancer cells, butyric acid-induced, 120:71 resistance to, during spontaneous Caco-2 cell differentiation, 120: 889 in epithelial cells prevention of, Cryptosporidium parvllmactivated factor KB and, 120: 1774 signal transduction during, 120:79, 120:294-e in hepatic stellate cells peripheral-type benzodiazepine receptor expression and, 120:1212, 120:1285-e in tissue injury, 120:1212, 120:1285-e in hepatocytes Fas-mediated, inhibition by bile acidactivated phosphatidylinositol 3-kinase (rodent), 120:1810 TNF-lX- and Fas-mediated, NF-KB stimulation of inducible nitric oxide synthase and (mouse), 120: 1251 PKC-B and, in Caco-2 cells, 120: 1700, 120:1868-e Appendectomy, laparoscopic, in patients with refractory ulcerative colitis, 120:1562-c Appetite, regulation of, ghrelin in, 120: 337-rc Arteriovenous malformations, hepatic, 120:1579-im

1910

SUBJECT INDEX

ASCA (anti-S"eeb"romyees eere,,;' si"e antJ.oody), assays, in inflammatory bowel disease, comparative study of, 120:827 Aschoff, Carl Albert Ludwig, 120: 1598

Ascites cuttent management of, 120:726 new-onset, treatment of, 120:726 refractory, management of, 120:311-ss, 120:726 Ashkenazi Jews, APe I1307K mutation in, and increased risk of colorectal cancer, 120:331-tmig, 120:392

ATP-binding cassette transporter At (ABCAt), and cholesterol metabolism, 120:1203

ATP7B (Wilson disease) protein, mutants localization of, 120:784-tmig, 120:967 properties of, 120:784-tmig, 120:967

AutoantJ.oodies in autoimmune hepatitis, 120:1502-srr in liver disease, 120:239-srr Autoimmune gastritis, proton pump as target autoantigen of Th 1-type cytotoxic T cells in, 120:377

Autoimmune hepatitis (AIR) autoantibodies in, 120: 1502-srr cholestatic disease and, 120: 1502-srr clinical presentation of, 120: 1502-srr definition of, 120: 1502-srr diagnostic criteria for, 120: 1502-srr differential diagnosis of, 120: 1502-srr genetic heterogeneity of, 120: 1502-srr histology of, 120: 1502-srr immunoserological heterogeneity of, 120: 1502-srr liver transplantation for, 120: 1502-srr natural history of, 120: 1502-srr prognosis for, 120: 1502-srr treatment of, 120: 1502-srr Autoimmune injury, hepatic, mechanisms of, 120:1485-srr

Azathioprine (AZA) for autoimmune hepatitis, 120:1502-srr for inflammatory bowel disease, 120:622 and 6-mercaptopurine, for refractory microscopic colitis, 120:1483-cr AZT. See Zidovudine

Backwash ileitis, and colorectal carcinoma risk, in ulcerative colitis, 120:783-tmig, 120:841 Bacteria, and colitis in TgE26 mice, 120:900 Bacterial overgrowth, in patients with gallstones, 120:1310-c Bacterial translocation, in cirrhosis, prokinetics and, 120:314-ss

GASTROENTEROLOGY Vol. 120, NO.7

Bariatric surgery, for obesity, 120: 669

Barrett's esophagus cancer risk with, 120:1617, 120:1630 dysplasia in, evaluation of, fluorescence, reflectance, and light-scattering spectroscopy for, 120: 1607, 120: 1864-e high-grade dysplasia in long-term nonsurgical management of, 120:1617, 120:1864-e and risk of carcinoma, 120:1630, 120: 1864-e photodynamic therapy for, persistent genetic abnormalities after, 120: 1064-c, 120:1065-c photodynamic therapy in, 120:785-gn Bax gene, and butyric acid-induced apoptosis in colon cancer cells, 120:71 Behavior therapy, for obesity, 120: 669 Beh~et's disease, gastrointestinal, antitumor necrosis factor monoclonal antibody therapy for, 120:995-cr Benzodiazepine receptor, peripheral type, and apoptosis induction in hepatic stellate cells, 120:1212, 120:1285-e

Bile acid composition, sterol 12a-hydroxylase expression and (rat), 120:1801 jejunal absorption of, neurotensin and (rat), 120: 151 metabolism, manipulation of, by activation of deorphanized nuclear receptors, 120: 1054 -ss synthesis of feedback regulation of, 120: 15 57-ss nuclear receptors and, 120: 15 57-ss Biliopancreatic diversion, for obesity, 120:669 BIM26226, and gastrointestinal motility, 120:331-tmig, 120:361 Blacks, colorectal cancer screening in, cost-effectiveness of, 120:848, 120:1043-e Bleeding, with angiodysplasias of gastrointestinal tract, abnormal von Willebrand factor in, 120:346 Brain, cortical and subcortical regions in, activation of, by gastric distention, 120: 369

Budd-Chiari syndrome G20210A ptothrombin gene mutation and, 120:1059-c survival with, factors affecting, 120:578-ss Budesonide, in autoimmune hepatitis, 120: 1502-stt

Butyrate cell differentiation and apoptosis induced by, resistance to, during spontaneous Caco-2 cell differentiation, 120:889 and 5-fluorouracil, antitumor synergy of, in human colorectal cancer xenografts, 120:874

Caffeine plus ephedrine, for obesity, 120:669

Calcitonin gene-related peptide (CGRP), and adaptive cytoproteetion in gastric mucosa, 120: 134 Calcium, influx, and mechanical tone in colon from dystrophic (mdx) mice, 120:1430 Calcium channels, L-type, in inflamed citcular smooth muscle cells of colon (dog), 120:331-tmig, 120: 480 Calcium-sensing receptor, in human anttal gasttin cells, mechanism of action of, 120:1128, 120:1279-e Camostat mesilate, in prevention of hepatic fibrosis (rat), 120:1784

Cancer anal. See Anal canal, cancer of celiac disease and, 120:636, 120:1526aga colon. See Colorectal cancer esophageal. See Esophageal carcinoma gastric. See Gastric cancer lung. See Lung cancer pancreatic. See Pancreatic cancer rectal. See Colorectal cancer rargeted chemotherapy for, LST-2 and, 120:1689 Carbon monoxide, from heme catabolism protects against hepatobiliary dysfunction (rat), 120:1227, 120:1288-e

Carcinogenesis in Caco-2 cells, PKC-o and, 120: 1700, 120:1868-e hepatic, pathways of, genetic alterations and,120:1763

Case Reports Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Beh~et's disease: a case report, 120:995 Development of interstitial cells of Cajal in a full-term infant without an enteric nervous system, 120:561 Diffuse esophageal leiomyomatosis with perirectal involvement mimicking Hirschsprung disease, 120:216

June 2001

Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene, 120:210 Human papillomavirus type 16-associated primary squamous cell carcinoma of the rectum, 120:988 Ischemic colitis during treatment with alosetron, 120:557 A new cause of Zollinger-Ellison syndrome: non-small cell lung cancer, 120:1271 Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving highly active antiretroviral therapy, 120:984 Treatment of refractory microscopic colitis with azathioprine and 6-mercapropurine, 120:1483 CD34, in human biliary epithelial progenitor cells, 120: 534 CDPS71, for active Crohn's disease, 120: 1317-tmig,120:1330

Celiac disease AGA medical position statement on, 120:1522-aga AGA technical review on, 120:1526-aga associated diseases, 120:636, 120:1526aga and auroimmune disease, 120:636 clinical features of, 120:636, 120: 1526aga complications of, 120: 1526 -aga definition of, 120:1526-aga diagnosis of, 120:636, 120:1526-aga epidemiology of, 120:636, 120:1526aga as food allergy, 120:1026-aga genetics of, 120: 1526 -aga historical perspective on, 120: 1526 -aga and malignancy, 120:636, 120:1526-aga pathogenesis of, 120:1526-aga pathology of, 120:1526-aga refracrory, 120:636 screening for, 120:636 limitations of anti-guinea pig liver transglutaminase IgA in, 120: 586-c treatment of, 120:636, 120: 1526 -aga types of, 120:1526-aga Cell c:yc:le, and intestinal cell differentiarion, 120:423 Chemoattrac:tants, epithelial characterization of, 120:60, 120:291-e interferon-inducible, production of, 120: 49, 120:291-e Chemokines, in regulation of lymphocyte homing ro intestinal mucosa, 120:49, 120:60, 120:291-e

SUBJECT INDEX

Chemotherapy nausea and vomiting caused by, 120: 263-aga targeted, in gastrointestinal cancer, LST-2 and, 120:1689

Child-Turcotte-Pugh c:lassification, of candidates for liver transplantation, 120:749

Chloride channels, epithelial cAMPdependent, sucrase-isomaltase as, 120:117, 120:299-e Chloride secretion, in intestinal epithelial T84 cells, potentiation of, by oxidants, 120:2-tmig, 120:89 Cholangiocarclnoma, Helicobaeter sp. in liver and, 120:323-c Cholangiocytes, oxidative DNA damage in, 120:190 Cholelithiasis, cholesterol colonic deoxycholic acid formation in, 120:1310-c MDR3 gene defect in, 120:1459, 120: 1549-e Cholestasis. See also Progressive familial intrahepatic cholestasis type 3 pathogenesis of, 119:321-c

Cholesterol absorption of, pancreatic phospholipase A2 and (mouse), 120:1193 metabolism of ATP-binding cassette transporter Al (ABCAl) and, 120:1203 manipulation of, by activation of deorphanized nuclear receptors, 120: 1054-ss

Cholesterol gallstones formation of chromosomal organization of candidate genes involved in (mouse), 120: 221-srr colonic deoxycholic acid formation in, 120:131O-c MDR3 gene defect and, 120:1459, 120: 1549-e Chromoendoscopy, 120:749

Cirrhosis

bacterial translocation in, prokinetics and, 120:314-ss complications of, current management of, 120:726 health-related quality of life in, 120: 170, 120:305-e Cisapride, and bacterial translocation in cirrhosis, 120: 314 -ss c-Jun N-terminal kinase (JNK), and butyric acid-induced apoptosis in colon cancer cells, 120:71

c-Id, gene germline mutation of, and familial gastrointestinal stromal tumor with hyperpigmentation, 120:21O-cr

1911

in human biliary epithelial progenitor cells, 120:534 Claudins, expression and subcellular localization of, in gastrointestinal tract, heterogeneity in (rat), 120: 411 Clevudine, therapy with, for hepatitis B, 120:1828-srr

Colitis chronic Crohn's, screening and surveillance colonoscopy in, 120:783tmig, 120:820 dextran sodium sulfate-induced, recovery from, in transgenic mice overexpressing growth hormone, 120: 925 experimental, differential role of selectins in, 120:1072-tmig, 120:1162 microscopic, treatment with azathioprine and 6-mercaptopurine, 120:1483-cr normal luminal bacteria and, in Tge26 mice, 120:900

Colon claudin expression and subcellular localization in, heterogeneity of (rat), 120:411 distal, findings in, and risk of proximal neoplasms, 120:1049-ss inflamed, L-type calcium channels in (dog), 120:331-tmig, 120:480 muscle in, tachykinin receptor NK 1 on, immunohistochemical demonstration of (guinea pig), 120:1140 peristalsis in, tachykinin-dependenr and -independent components of (guinea pig), 120:938 proximal, from dystrophic (mdx) mice, mechanical tone of, calcium influx and, 120:1430 in vivo absorption of medium-chain fatty acids versus short-chain fatty acids (rat), 120:1152 Colon cancer. See Colorectal cancer Colonic crypts, Na+-dependent fluid absorption in (rat), 120: 144 Colonic transit, and deoxycholic acid metabolism in cholesterol cholelithiasis, 120:1310-c

Colonoscopy in Crohn's disease, 120:783-tmig, 120: 820 virtual, as screening tool, 120:1073-gn Colorec:tal cancer. See also Hereditary nonpolyposis colorectal cancer (HNPCC) antitumor synergy of 5-f1uorouracil and 3n-butyrate in, 120:874

1912

GASTROENTEROLOGY Vol. 120, No. 7

SUBJECT INDEX

Caco-2 cells differentiation of, phosphatidylinositol 3-kinase and, 120:1317-tmig, 120:1381,120:1543-e partial reversion of malignant phenorype in, PKC-l) and, 120:1700, 120:1868-e resistance to butyrate-induced cell differentiation and apoptosis, 120:889 chemotherapy for, microsatellite instability as prognostic indicator in, 120:1309-c circulating tumor cells in peripheral blood of patients wirh, prognostic significance of, 120: 1071tmig, 120:1084 growrh of, COX-2 and HER-2/neu inhibitors and, 120:1713, 120: 1872-e individuals at risk for, identification of, 120:1317-tmig,120:1356 inflammatory bowel disease and, 120: 783-tmig, 120:820, 120:841, 120:1317-tmig, 120:1356 pathogenesis of, colonic luminal contents and, 120:332-tmig, 120:401 prevention of, advances in (future directions for), 120:3-gn risk of, with APe I1307K mutation in Ashkenazi Jews, 120:331-tmig, 120:392 screening for, 120:333-gn in chronic Crohn's colitis, 120:783tmig, 120:820 colonoscopy in, 120:1049-ss, 120: 1051-ss distal colonic findings in, and risk of proximal neoplasms, 120:1049-ss racial/ethnic patterns of disease and, 120:848, 120:1043-e virtual colonoscopy in, 120:1073-gn surveillance colonoscopy for, in chronic Crohn's colitis, 120:783-tmig, 120:820 in ulcerarive colitis parients backwash ileitis and, 120:783-tmig, 120:841 p53 gene and, 120:1877-ss Combivir. See ZDV-3TC

Comment From the Editors Editorial transition, 120: 1577 Entangled in a Web(site)?, 120:1321 GERD remains an intriguing enigma, 120:787 Postapproval dtug surveillance and the first principle of medicine, 120:5 Pump up the volume: a sound policy?, 120:1075

Remembering John Walsh: One of the prophets of GI, 120:335

Complement activation of, induced by He/icobacter pylori, 120: 1108 C5, inhibirion of, effect on local and remote organ injury after intestinal ischemia-reperfusion (rat), 120:126 resistance to, by protectin-bound Helicobacter pylori, 120:332-tmig, 120: 470 Computed tomography (CT), of pancreas, in diagnosis of pancreatitis, 120:682

Constipation functional, prucalopride for, 120:331tmig, 120:354 historical perspective on, 120:317-pmr

Correspondence Abnormal hepatic sinusoidal bile acid transport: new insights into the pathogenesis of cholestasis?, 120: 321 API2-MALTI chimeric transcript is a predictive marker for the responsiveness of H. pylori eradication treatment in low-grade gastric MALT lymphoma, 120:1884 Differential HFE allele expression in hemochromatosis heterozygotes, 120:1308 G20210A prothrombin gene mutation and other thrombophilic polymorphisms in patients with portal or hepatic venous thrombosis, 120:1059 Helicobacter pylori infection and gastric cancer, 120:324 Helicobacter species identified in liver from patients with cholangiocarcinoma and hepatocellular carcinoma, 120:323 Heparin therapy for ulcerative colitis, 120:1307 Hepatitis B infection in heart transplant recipients, 120:1311 Hepatitis B virus genotypes and hepatocellular carcinoma in Japan, 120: 1564 Identification of motilin-related peptide, 120:588 Increased levels of factor VIII:C as a possible risk factor for portal, splenic, and mesenteric vein thrombosis, 120:1563 Intestinal motility and bacterial overgrowth in patients with gallstones, 120: 131 0

Intractable insomnia after cessation of treatment with thalidomide, 120: 1567 Laparoscopic appendectomy in patients with refractory ulcerative colitis, 120:1562 Limitations of anti-guinea pig liver transglutaminase IgA in screening of celiac disease, 120:586 Mesalamine maintenance therapy for Crohn's disease, 120:585 Microsatellite instability as a molecular marker for very good survival in colorectal cancer patients receiving adjuvant chemotherapy, 120: 1309 Motilin-related peptide and ghrelin: lessons from molecular techniques, peptide chemistry, and receptor biology, 120:587 Mutations of the pancreatic secretory trypsin inhibitor (PST!) gene in idiopathic chronic pancreatitis, 120:1061 Optimal cases and sites to search for primary microbial agents in Crohn's disease, 120:1066 Organic anion-transporting polypeptides: expression cloning and functional tests, 120:1887 Organization of intestinal pacemakers, 120:319 Pathogenesis of diclofenac enteropathy, 120:1885 Photodynamic therapy and genetic abnormalities, 120:1065 Significance of genetic abnormalities after photodynamic therapy, 120: 1064 Somatic mutation of the I3rmicroglobulin gene associates with unfavorable prognosis in gastrointestinal cancer of the microsatellite mutator phenotype, 120:1565 SPINK] mutations in chronic pancreatitis, 120: 1060 Successful orthotopic liver transplantation, 120: 1561 Variability of serologic testing for H. pylori using U.S. and Peruvian antigens, 120:325 When can unfractionated heparin really be useful in the treatment of ulcerative colitis?, 120:1306 Why the mesenteric margin?, 120:1885 Couric, Katie, and CRC screening, 120: 333-gn

Cow's milk allergy disordets associated with, 120:1026-aga gastroesophageal reflux disease associated with, in infants, 120:1026-aga

SUBJECT INDEX 1913

June 2001

Coxib, therapy with, during NSAID use, 120:594 Crbdvan. See Indinavir

Crohn's disease (CD) ASCA (anti-Saccharomyces cerevisiae antibody) assays in, comparative study of, 120:827 course of, smoking cessation and, 120: 1071-tmig, 120:1093 maintenance of remission in, methotrexate for, 120:1553-ss mesalamine maintenance therapy for, 120:585-c patient education about, 120:317-pmr perianal fistulae in, initial medical management for, cost-utility of, 120: 1640 primary microbial agents in, optimal cases and sites to search for, 120: 1066-c screening and surveillance colonoscopy in, 120:783-tmig, 120:820 treatment of, 120:317-pmr anti-lNF antibody for, ANCA pattern and LTA haplotype and, 120: 1347 engineered human antibody to TNF (CDP57l) for, 120:1317-tmig, 120:1330 novel therapies for, 120:308-ss subcutaneous antisense ICAM-l for, absence of efficacy of, 120:1317tmig, 120:1339 Cryptosporidiosis, in HIV-infected (AIDS) patient, HAART-related resolution of, 120:984-cr CryJlloqorl4....... enterocyte resistance against, IFN-'Ymediated, 120:99 and NF-KB activation in biliary epithelia, and prevention of epithelial cell apoptosis, 120:1774 Cyclooxygenase (COX), COX-2 and colorectal carcinoma growth, 120: 1713, 120:1872-e and gastroprotective prostaglandins, 120: 784-tmig, 120:867 inhibitor, therapy with, during NSAID use, 120:594 and persistent postinfective enteric muscle dysfunction (mouse), 120: 1713 lNF-a-induced expression of, in colonic epithelial cells, phosphatidylinositol 3-kinase and, 120:1117 transcription in human colon carcinoma cells, colonic luminal contents and, 120:332-tmig, 120:401 Cyclophosphamide, for autoimmune hepatitis, 120:1502-srr

lH''''''''''''

Cyclosporine for autoimmune hepatitis, 120:1502-srr as single therapy for acute ulcerative colitis, 120:1317-tmig, 120:1323, 120:1541-e

Cystic fibrosis transmembrane conductance regulator, mutations, and chronic pancreatitis, 120:682

Cytochrome P-4S0 CYP8b1, and regulation of bile acid pool composition (rat), 120:1801 CYP4502E1, ethanol-induced, and retinoic acid metabolism (rat), 120: 179 Cytokines, therapy with, for hepatitis B, 120:1828-srr

MC. See Zalcitabine cIdI. See Didanosine Delavirdine, GI toxicity and GI-associated drug interactions of, 120: 607 Dendritic cells, impaired allostimulatory function of, in chronic hepatitis C, 120:512 Deoxycholic add, colonic formation of, and cholesterol cholelithiasis, 120:131O-c

Dermatitis herpetif'ormis, 120: 1526-aga

Developmental biology, of gastrointestinal tract, 120:1883-pmr

Diabetic gastropathy, sildenafil therapy in animal models of, 120: 576-ss Diarrhea, acute, in childten, management of, 120:783-tmig, 120:799 Diclofenac, enteropathy induced by, pathogenesis of, 119:1885-c Didanosine, GI toxicity and GI-associated drug interactions of, 120: 607 Diet therapy, for obesity, 120:669 Disaccharides, and IL-8 and IL-l f3 secretion by intestinal epithelial cells, 120:449

Divalent metal transporter 1 expression of, in iron deficiency and iron overload, 120:1317-tmig, 120: 1412 intestinal iron uptake determined by, in HFE-deficient mice with hemochromatosis, 120:1420

DNA (deoxyribonucleic add) base excision repair, nitric oxide-mediated inhibition of, 120:190 oxidative damage, in cholangiocytes, 120:190

Drug development, postapproval surveillance in, and interests of patients, 120:5-ce d4T. See Stavudine Duodenal switch, for obesity, 120:669 Dyspepsia, management of, 120:1298-ss

Economics of colorectal cancer screening, racial/ethnic patterns of disease and, in U.S., 120:848, 120:1043-e of HCFA policy, effects on gastroenterologists and Medicare patients, 120:3-gn of initial medical management for Crohn's disease perianal fistulae, 120:1640 of managing GI risk in patients taking NSAIDs, 120:594 of research funding initiative in Germany, 120:334-gn

Editorials Apoptosis-programmed cell death and its relevance to gastrointestinal epithelium: survival signal from the matrix, 120:294 Carbon monoxide and sepsis: is a toxic gas good for your liver?, 120: 1288 Chemokines regulate lymphocyte homing to the intestinal mucosa, 120:291 Chronic liver disease and health-related quality of life, 120:305 Colorectal cancer: not an equal opportunity cancer, 120:1043 Disputing dysplasia, 120:1864 Epidermal growth factor receptor blockade: an emerging therapeutic modality in gastroenterology, 120:1872 Gastric cardia cancer and dietary fiber, 120:568 GLP-2 as therapy for the short-bowel syndrome, 120:1041 How can mathematics help us understand HCV?, 120:1546 Human papillomavirus infection: an emerging problem in anal and other squamous cell cancers, 120: 1046 Identification of a new chloride channel: a sweet story?, 120:299 Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue, 120:1281 Intravenous cyclospotine in severe ulcerative colitis: ready to stand alone?, 120:1541 Irritable bowel syndrome in childhood, 120:287

1914 SUBJECT INDEX

Is EX01 a colon cancer predisposirion gene?, 120:1860 Liver fibrosis and Na+/H+ exchange, 120:572 MDR3 mutations: a glimpse into Pandora's box and the future of canalicular parhophysiology, 120:1549 Octreotide and its effects on portal circulation, 120:303 Progress in understanding acalculous gallbladder disease, 120:570 Protein kinase C isozymes in colon carcinogenesis: guilt by omission, 120:1868 Sugar pills for pancreatic cancer: the benefits of becoming (insulin) sensitive, 120:1291 Transepithelial signaling: making sense of stomach contents, 120:1279 The up-and-down of hepatic stellate cells in tissue injury: apoptosis restores cellular homeostasis, 120:1285 Will impedance testing rewrite the book on GERD?, 120:1862 The Yin and Yang of intestinal differentiation: key roles for lipid signaling, 120:1543 Efamenz, GI toxicity and GI-associated drug interactions of, 120:607 Emtrldtabine, therapy with, for hepatitis B, 120:1828-srr Endoscopic diagnostics, 120:763, 120: 1304-pmr

Endoscopic retrograde cholangiopancreatography (ERCP), pancreatitis induced by, prorection against, by IL-10, 120:332tmig, 120:498

Endoscopic retrograde pancreatography (ERP), in diagnosis of pancreatitis, 120:682

Endoscopic ultrasound, in diagnosis of pancreatitis, 120:682

Endoscopy in follow-up of high-grade dysplasia in Barrett's esophagus, 120:1617 gastrointestinal, 120: 1304-pmr Enteral nutrition, for alcoholic hepatitis, 120:1053-ss Enteric nervous system, and development of interstitial cells of Cajal, in human small intestine, 120:561-cr Enterocolitis syndrome, dietary (food) protein-induced, 120:1026-aga Enteroc:ytes, high-affinity basolateral glycine uptake in, GLYTl and, 120:439

Enteropathy diclofenac, pathogenesis of, 119:1885-c

GASTROENTEROLOGY Vol. 120, No.7

dietary (food) protein-induced, 120:1026-aga Enzyme, functioning as ion channel, 120: 117,120:299-e Eosinophilic esophagitis, and GER, in adults and children, 120: 1026-aga Eosinophilic gastroenteritis, 120: 1026-aga

Epidermal growth factor (EGF) receptor blockade and colorectal carcinoma growth, 120: 1713,120:1872-e therapeutic applications of, 120: 1713, 120:1872-e and stress-induced expression of EGFlike growth factors in gastric epithelial cells (rat), 120:108 Epilepsy, abdominal, 120:263-aga

Epithelium apoptosis in, signal transduction during, 120:79, 120:294-e biliary Cryptosporidium parvum and NF-KB activation in, and prevention of epithelial cell apoptosis, 120: 1774 progenitor cells of, 120: 534 cell biology in, keratin 19 promoter in, 120:1728 colonic absorption of medium-chain fatty acids (rat), 120:1152 resistance to butyrate-induced cell differentiarion and apoprosis, 120:889 TNF-a-induced COX-2 expression in, phosphatidylinositol 3-kinase and, 120:1117 follicle-associated, lymphocyte-dependent development of, in Peyer's patches (mouse), 120:1173 gastric, stress-induced expression of EGF-like growth factors, EGFRmediated (rat), 120:108 intestinal cell differentiation in, cell cycle and, 120:423 chloride secretion in, potentiation of, by oxidants, 120:2-tmig, 120:89 dysfunction, caused by inhibition of Na+, K+ -ATPase by interferon 'Y, 120: 1393 hPepTl expression in, in inflammatory bowel disease, 120:1657 IL-8 and IL-ll3 secretion by, disaccharides and, 120:449 lymphocyte chemoattractants produced by characterization of, 120:60, 120:291-e production of, 120:49, 120:291-e

tachykinin receptor NK 1 on, immunohistochemical demonstration of (guinea pig), 120:1140 Epivir. See Lamivudine ErbB receptor, HER-2Ineu, and colorectal carcinoma growth, 120: 1721, 120:1872-e

Esophageal eardnoma photodynamic therapy for, 120:785-gn risk of, high-grade dysplasia in Barrett's esophagus and, 120:1617, 120: 1630 Esophageal manometry, for diagnosis of achalasia, 120:783-tmig, 120:789 Esophagus. See a/so Barrett's esophagus diffuse leiomyomatosis of, 120:216-cr high-grade dysplasia in, photodynamic therapy for, 120:785-gn nerve-mediated contractions in, tachykinins and, 120:1-tmig, 120:39

Ethanol and chronic pancreatitis, 120:682 induction of CYP4502E1, and retinoic acid metabolism (rat), 120:179 liver disease caused by, risk of, homozygosity for alanine in mitochondrial targeting sequence of SOD and, 120:1318-tmig, 120:1468 liver injury caused by, reduction of, by superoxide dismutase (rat), 120: 1241 Etodolac, gastrointestinal events related to, risk of, 120:594 Exercise therapy, for obesity, 120:669 EXO~ gene, germline variants of, in hereditary nonpolyposis colorectal cancer, 120:1580-rc, 120:1860-e

Farnesoid X receptor, and cholesterol and bile acid metabolism, 120: 1054-ss Fas protein, apoptosis mediated by, inhibition by bile acid-activated phosphatidylinositol 3-kinase (rodent), 120:1810 Fat digestion, and modulation of gastrointestinal sensations in gastric distention, 120: 1071-tmig, 120: 1100 Fatty adds, medium-chain, colonic absorption of (rat), 120:1152

Fenfluramine plus phentermine, for obesity, 120:669

Ferroportin 1, expression of, in iron deficiency and iron overload, 120: 1317-tmig,120:1412

SUBJECT INDEX

June 2001

Fiber, dietary intake of, and risk of gastric cardia cancer, 120:331-tmig, 120:387, 120:568-e in treatment of irritable bowel syndrome, 120:652 nel gene, mutation, in Amish kindred, 119:321-c ;"F1uorouradl, and 3n-butyrate, antitumor synergy of, in human colorectal cancer xenografcs, 120:874 Focal adhesion kinase, cleavage of, during apoptosis, 120:79, 120: 294-e

Food allergy clinical manifestations of, 120:1026-aga diagnostic criteria for, 120:1026-aga epidemiology of, 120: 1026-aga evaluation of AGA technical review on, 120:1026--aga guidelines for, AGA medical position statement on, 120:1023-aga pathophysiology of, 120:1026-aga

Food and Drug Administration (FDA), proposal to increase public access to information on xenotransplantation and gene therapy trials, 120:786-gn Food protein, immediate (IgE-mediated) gastrointestinal reactions to, 120:1026-aga Fortovase. See Saquinavir

GABAB receptors, and vagal motor control of lower esophageal sphincter, 120:1749

Gallbladder chronic acalculous disease of, muscle dysfunction in, 120:506, 120:570-e contraction of, GRP receptor blockade and, 120:331-tmig, 120:361 motility, and chronic acalculous disease, 120:506, 120:570-e Gallstones, cholesterol, formation of, chromosomal organization of candidate genes involved in (mouse), 120:221-srr Gastric: add, secretion, KCNQl in, 120:1363 Gastric: banding, for obesity, 120:669 Gastric: bypass, for obesity, 120:669

Gastric: cancer

of cardia, cereal fiber intake and, 120: 331-tmig, 120:387, 120:568-e Helicobaeter pylori and, 120:324-c

Gastric: distention cortical and subcortical regions activated by, 120:369 gastrointestinal sensations induced by, fat digestion and, 120:1071tmig, 120:1100

Gastric: emptying, GRP receptor blockade and, 120:331-tmig, 120:361

Gastrin-releasing peptide (GRP) rec:eptors, in gastric emptying, gallbladder contraction, and small intestinal transit, 120:331tmig, 120:361 Gastritis, autoimmune, proton pump as target autoantigen of Thl-type cytotoxic T cells in, 120:377

GASTROENTEROLOGY editorial transition, 120: 1577-ce special issue on therapeutics and diagnostics, introduction to, 120:593 Gastroenterology, evidence-based, 120:1559-pmr

Gastroenterology News Bill seeks to reform, educate on Medicare regulations, 120: 1320 Biomedical research funding on the rise in Japan, 120:1074 Couric, Tartikoff to push CRC screening message in March, 120:333 FDA seeks to increase access to information on xenotransplantation, gene therapy trials, 120:786 The future of colon cancer prevention, 120:3 HCFA policy hurts gastroenterologists and Medicare patients, AGA charges, 120:3 Major funding initiative in Germany enhances research efforts, 120:334 New AGA president outlines goals, 120: 786 New leadership in Washington: implications for gastroenterology, 120:333 Nutrition and obesity, xenotransplantation among topics to be covered at DDW 2001, 120:1073 Nutrition moves beyond weighty issues, 120:1319 Pegylated interferon for treatment of hepatitis C, 120:3 Photo finish for Barrett's esophagus, other digestive tract lesions?, 120:785 Radiologist sees a future for virtual colonoscopy as screening tool, 120:1073 Student loan burden may be eased, 120:1320

Gastroesophageal reflux disease (GERD), 120:583-pmr acid, nonacid, and gas, during 24-hour pH-impedance recordings, 120: 1588, 120:1862-e acid and nonacid, simultaneous intraesophageal impedance and pH measurement of, effect of omeprazole, 120:1599, 120:1862-e

1915

associated with cow's milk allergy, in infants, 120:1026-aga diagnosis of, 120:787-ce eosinophilic esophagitis and, in adults and children, 120:1026-aga pathogenesis of, 120:787-ce treatment of, 120:787-ce

Gastrointestinal motility, 120:1056-pmr mechanisms for, 120:331-tmig, 120: 361, 120:480 tachynergic and cholinergic transmission in, 120:938

Gastrointestinal stromal tumor, familial, with hyperpigmentation, c-kit gene mutation and, 120: 21O-cr Gastrointestinal tract, claudin expression and subcellular localization in, heterogeneity of (rat), 120:411

Gastrointestinal transit GRP receptor blockade and, 120:331tmig, 120:361 prucalopride and, in functional constipation, 120:331-tmig, 120:354

Gastroparesis intractable nausea and vomiting with, 120:263-aga therapy for, 120:576-ss Gastroplasty, for obesity, 120:669 G c:ells, calcium-sensing receptor on, mechanism of action of, 120: 1128, 120:1279-e Gene therapy, trials of, information on, FDA seeks to increase access to, 120:786-gn Genetic: testing, for hereditaty nonpolyposis colorectal cancer, microsatellite instability and, 120:1-tmig, 120:21

Ghrelia and appetite regulation, 120:337-rc and motilin-related peptide, 120:587-c, 120:588-c structure of, 120:337-rc Glisson, Francis, 120:1362 Glucagon-like peptide 2, in treatment of shore-bowel syndrome, 120:783-tmig, 120:806, 120: 1041-e

Gluten in medications, 120:636 total avoidance of, in treatment of celiac disease, 120:636, 120:1526-aga Glycine, high-affinity basolateral uptake of, in enterocytes, GLYTI and, 120:439 Goblet c:ells, differentiation of, regulation by keratinocyte growth factor, 120:1372

1916

GASTROENTEROLOGY Vol. 120, No. 7

SUBJECT INDEX

Growth hormone (GH) and recovery from dextran sodium sulfate-induced colitis (mouse), 120:

925 therapy with, for Crohn's disease, 120: 308-ss

Halsted, William Stewart, 120:386 Health Care Finance Administration, policy, effects on gastroenterologists and Medicare patients, 120:3-gn Health care quality, volume/outcome relationship in, 120:1075-ce Health-related quality of life, in chronic liver disease, 120:170, 120:305-e Heart transplantation, recipients hepatitis Bin, 120:1311-c viral hepatitis in, 120:1561-c Heidenhain, Rudolf, 120:1083 H.'~ sp., in liver from patients with cholangiocarcinoma and hepatocellular carcinoma, 120:323-c

H.'1eo1Hlelfto pylon complement activation induced by, 120: 1108 eradication in gastric MALT lymphoma, API2MALTI chimeric transcript as predictive marker for responsiveness to, 120:1884-c versus prompt endoscopy, for dyspepsia, 120:1298 -ss and gastric cancer, 120:324-c and NSAID use, 120:594 protectin-bound complement-induced lysis prevented by, 120:332-tmig, 120:470 prevention of complement-induced lysis, 120:332-tmig serologic testing for, using U.S. and Peruvian antigens, 120:325-c Heme catabolism, carbon monoxide from, and protection against hepatobiliary dysfunction (rat), 120:1227,120:1288-e

Hemochromatosis clinical features of, 120:718 diagnosis of, 120:718 differential HFE allele expression in, 120:1308-c duodenal expression of stimulator of Fe transport and transferrin receptor in, 120:1404 genetics of, 120:718 in HFE-deficient mice, and intestinal iron uptake determined by divalent metal transporter 1, 120: 1420

management of, 120:718 pathophysiology of, 120:718 screening for fiunily, 120:718 population, 120:718 Heparan sulfate, disaccharides derived from, and 11-8 and 11-1~ secretion by intestinal epithelial cells, 120:449

Heparin disaccharides derived from, and IL-8 and IL-l ~ secretion by intestinal epithelial cells, 120:449 unfractionated, for ulcerative colitis, comparison with methylprednisolone, 120:1306-c, 120:1307-c Hepatic vein, thrombosis, G20210A prothrombin gene mutation and, 120:1059-c

Hepatitis alcoholic, nutritional therapy for, 120: 1053-ss autoimmune. See Autoimmune hepatitis (AIH) viral, in heart transplant recipients, 120: 1311-c, 120:1561-c

Hepatitis BlHepatitis B viru5 (HBV) advanced, antiviral therapy for, 120:1828-srr animal models of, 120:1828-srr chronic acute /lares of, 120:1009-srr in children, 120:1828-srr gene expression in, eDNA microarray analysis of, 120:955 HBeAg-negative interferon a therapy in, 120:1828srr lamivudine therapy for, 120:1828srr HBeAg-positive interferon a therapy in, 120:1828srr lamivudine therapy for, 120:1828srr liver hisrology in, 120:1828-srr DNA, tests for, 120:1828-srr drug resistance in, molecular anatomy and pathophysiologic implications of, 120:1000-srr epidemiology of, 120: 1828 -srr /lares of antiviral therapy-induced, 120: 1009srr HBV genotypic variation and, 120: 1009-srr lamivudine therapy and, 120:1000-srr other viral infection and, 120:1009srr

genotypes, and hepatocellular carcinoma, in Japan, 120:1564-c in heart transplant recipients, 120:1311-c, 120:1561-c and hepatocellular carcinoma, surveillance for, 120:1828-srr immunopathogenesis of, 120:1828-srr lamivudine resistance in, 120: 1828-srr natural history of, 120:1828-srr polymerase, 120:1OO0-srr recurrence after liver transplantation prevention of combination therapy for, 120:1828-srr HBlg for, 120:1828-srr treatment of, 120:1828-srr treatment of in HIV-infected (AIDS) patients, 120: 1828-srr molecular approaches to, 120:1828srr nucleoside analogs for, 120:1828-srr recommendations for, 120:1828-srr vaccine against, 120:1828-srr and multiple sclerosis, 120:1880-ss variants and mutants of, 120:1828-srr virology of, 120:1828-srr

Hepatitis CIIIepatitis C viru5 (ReV) chronic allostimulatory defect of dendriric cells in, 120:512 gene expression in, eDNA microarray analysis of, 120:955 in heart transplant recipients, 120:1561-c hepatic fibrosis in, response to interferon therapy, 120:579-ss in HIV-infected (AIDS) patients, management of, 120:607 information on, for children, 120: 1056pmr management of, 120:1878-ss mother-to-child transmission of, prevention of, 120:1555-ss outcome of, predicrion of, 120:312-ss prognosis for, 120:1878-ss quasispecies of, prognostic significance of, 120:312-ss recurrence of, after liver transplantation, 120:749 treatment of, pegylated interferon for, 120:3-gn viral kinetics with, 120:1318-tmig, 120:1438, 120:1546-e

Hepatocellular carcinoma (HCe) genetic alterations in, 120: 1763 HBV genotypes and, in Japan, 120:1564-c Helicobacter sp. in liver and, 120:323-c prevention of, by interferon, 120:1301-ss

June 2001

surveillance for, in hepatitis B, 120:1828-srr

Hepatocytes

Fas-mediated apoptosis in, inhibition by bile acid-activated phosphatidylinositol 3-kinase (rodent), 120: 1810 TNF-a and Fas-mediated apoptosis in, NF-KB activation and iNOS in (mouse), 120:1251 transplantation of, 120:749 Hepatology, evidence-based, 120:1559pmr Hepatorenal syndrome, treatment of, 120:726 Hereditary hemochromatosis. See Hemochromatosis

Hereditary nonpolyposis colorectal cancer (HNPCC) atypical, germline variants of EXOI gene in, 120:1580-rc, 120:1860-e detection of, by screening for tumor microsatellite instability before germline genetic testing, 120:1tmig, 120:21 HER-:J/...." and colorectal carcinoma gtowth, 120:1713, 120:1872-e

HFBgen.e differential allelic expression of, in hemochromatosis, 120:1308-c knockout models of, 120:718 mutations, analysis of, in liver disease, 120:718

Highly active antiretroviral therapy(HAART) GI-associated drug interactions of, 120: 607 for HIV-1 infection adverse effects and side effects of, 120: 607 efficacy of, 120:607 and mucosal immunity, 120:984-cr

llirsc:hsprung's disease differential diagnosis of, 120:216-cr single-stage operations for, 120:1299-ss Histoac:ryl, in management of gastric varices, 120:1875-ss HIVID. See Zalcitabine HIV·infected (AIDS) patients. See also Human immunodeficiency virus (HIV-l) hepatitis B in, treatment of, 120:1828srr hepatitis C in, management of, 120:607 H+,K+-ATPase. See Proton pump hPepTI, colonic epithelial expression of, in inflammatoty bowel disease, 120:1657

Human Jmmunoclefidenc:y virus (HIV-I). See also HIV-infected (AIDS) patients

SUBJECT INDEX

infection management of, gastrointestinal aspects of, 120:607 pathogenesis of, gastrointestinal aspects of, 120:607 transmission of, gastrointestinal mucosa and, 120:607

Human papilloma virus (HPV) and high-grade dysplasia in anal canal, 120:784-tmig, 120:857, 120: 1046-e and risk of anal canal cancer, 120:784tmig, 120:857, 120:1046-e type 16, and primaty squamous cell carcinoma of rectum, 120:988-cr, 120:1046-e Hydroxyurea, therapy with, GI toxicity and GI-associated drug interactions of, 120:607 Hyperc:alcemia, and chronic pancreatitis, 120:682 Hyperlipidemia, and chronic pancreatitis, 120:682 Hyperpigmentation, familial gastrointestinal stromal tumor with, 120: 21O-cr Hypnotherapy, in treatment of irritable bowel syndrome, 120:652

Ibuprofen, gastrointestinal events related to, risk of, 120:594

fields, after intracellular parasite infection, regulation by TGF-~-pro­ ducing intraepithelial lymphocytes (mouse), 120:914

Image of the Month complications of endoscopic variceal sclerotherapy, 120:336 hepatic arteriovenous malformations, 120:1579 ileocecal tuberculosis, 120:1076 pheochromocytoma, 120:6 Salmonella aortitis, 120:1322 von Hippel-Lindau (VHL) disease, 120:788 Immune cells, hepatic, 120:250-srr Immunodiagaostic:s, in inflammatoty bowel disease, 120:622 Immunoglobulin A, anti-guinea pig liver transglutaminase, in screening for celiac disease, limitations of, 120:586-c Immunomod.ulation, for inflammaroty bowel disease, 120:622

Immunosuppression for autoimmune hepatitis, 120:1502-srr evolving strategies for, 120:749 historical perspective on, 120:749 for inflammatoty bowel disease, 120:622 Impedance testing, in gastroesophageal reflux disease, 120:1588, 120:1599, 120:1862-e

1917

Indina., GI toxicity and GI-associated drug interactions of, 120:607

Indomethadn gastrointestinal events related to, risk of, 120:594 inflammation induced by, vascular anatomy in, 120:1885-c

Inflammation

colonic, down-regulation of L-type calcium channels in (dog), 120:331tmig, 120:480 in ischemia-reperfusion injuty, PPAR'Y and (mouse), 120:332-tmig, 120: 460 mucosal, normal luminal bacteria and, in Tge26 mice, 120:900

Inflammatory bowel disease (IBD). See also Crohn's disease (CD); Ulcerative colitis (UC) ASCA (anti-SaccharomyceJ cerevisiae antibody) assays in, 120:827 colonic epithelial hPepTl expression in, 120:1657 and colorectal cancer risk, 120:783-tmig, 120:816, 120: 820, 120:841 family histoty and, 120:816, 120:1317-tmig, 120:1356 diagnosis of, 120:622, 120:1057-pmr ecotherapeutics for, 120:622 immunodiagnostics of, 120:622 immunotherapeutics for, 120:622 management of, 120:622, 120:1057-pmr new modalities for, 120:1317-tmig, 120:1323, 120:1330, 120:1339 probiotic rherapy in, 120:622, 120:1297-5s in spouses and their offspring, 120:816 susceptibility locus for, on X chromosome, evidence for, 120:834 treatment of, growth hormone as potenrial agent in, 120:925

lofliximab for Crohn's disease, clinical responses to, effect of ANCA pattern and LTA haplotype on, 120:1347 for gastrointestinal Beh~et's disease, 120: 995-cr for initial medical management of Crohn's perianal fistulae, costutility of, 120:1640 Infrared imaging, 120:749 Insomnia, intractable, after cessation of thalidomide therapy, 120:1567-c

Insulin resistance and obesity, in pancreatic carcinogenesis, 120:1072-tmig, 120:1263, 120: 1291-e and pathogenesis of nonalcoholic steatohepatitis, 120:1183, 120:1281-e

1918

GASTROENTEROLOGY Vol. 120, No.7

SUBJECT INDEX

IlIterferon effect on hepatic fibrosis in chronic hepatitis C, 120:579-ss IFN-a fot children with chronic hepatitis B, 120: 1828-srr effect on natural history of chronic hepatitis B, 120:1828-srr for HBeAg-negative chronic hepatitis B, 120:1828-srr for HBeAg-positive chronic hepatitis B, 120:1828-srr plus lamivudine, therapy with, in chronic hepatitis B, 120:1828srr IFN-13, and prevention of hepatocellular carcinoma in hepatitis C, 120: 1301-ss IFN-')I effects on intestinal epithelial transport and barrier function, 120:1393 and enterocyte resistance against Cryptosporidium parvum, 120:99 pegylated, for hepatitis C, 120:3-gn viral kinetics with, 120:1318-tmig, 120:1438, 120:1546-e

Interleuldn(s) IL-2, therapy with, GI toxiciry and GIassociated drug interactions of, 120:607 IL-8 and IL-I13, secretion by intestinal epithelial cells, disaccharides and, 120:449 IL-I0 protection against ERCP-induced pancreatitis, 120:332-tmig, 120:498 therapy with, in inflammatory bowel disease, 120:1297-ss llIternet, medical information on, 120: 1321-ce Interstitial cells of Cajal, development of, enteric nervous system and, in human small intestine, 120:561-cr Intestinal metaplasia, diagnosis of, Optical coherence tomography in, 120:1-tmig, 120:7 Inrirase. See Saquinavir Iron. See also Stimulator of Fe transport (Sm duodenal absorption of, effect on iron homeostasis, 120:1317-tmig, 120:1412 intestinal uptake of, by divalent metal transporter 1, in HFE-deficient mice with hemochromatosis, 120: 1420

Iron deficiency duodenal expression of stimulator of Fe transport and transferrin receptor in, 120:1404

expression of divalent-metal transporter 1 and ferroportin 1 in, 120:1317tmig, 120:1412 Iron overload syndromes. See also Hemochromatosis classification of, 120:718 expression of divalent-metal transporter 1 and ferroportin 1 in, 120:1317tmig, 120:1412 Irritable bowel syndrome (188), 120:1559-pmr in children, 120:1-tmig, 120:31, 120: 287-e diagnostic criteria for, 120:652 epidemiology of, 120:652 management of, 120:652 novel and experimental therapies for, 120:652 natural history of, 120:652 pathophysiology of, 120:652 variants of, 120:652

Ischemia-reperfusion injury anti-inflammatory activity in, PPAR')I and (mouse), 120:332-tmig, 120: 460 intestinal complement C5 inhibition and (rat), 120:126 remote organ injury after, complement C5 inhibition and (rat), 120:126 Ischemic colitis, during a1osetron therapy, 120:557-cr Isenberg, Jon I., President of AGA, 120:1518-aga goals of, 120:786-gn

Japan biomedical research funding in, 120: 1074-gn HBV genorypes and hepatocellular carcinoma in, 120:1564-c Jejunoileal bypass, for obesity, 120: 669 Jejunum, bile acid absorption in, neurotensin and (rat), 120:151 Julius M. Friedenwald Medal, presentation to Don W. Powell, 120:1854-aga

Kaletra. See ABT 378 Keratinocyte growth factor, and goblet cell differentiation, 120: 1372 Keratin promoter, and cell-specific targeting of genes in transgenic mice, 120:1728 Ketorolac, gastrointestinal events related to, risk of, 120:594 lUlpffer cen, in alcoholic steatosis (rat), 120:581-ss

l'

Lamivudine for chronic hepatitis B and development of YMDD mutant virus, 120:1000-srr, 120:1561-c in HBeAg-negative disease, 120: 1828-srr in HBeAg-positive disease, 120:1828srr GI toxicity and GI-associated drug interactions of, 120:607 plus IFN-a, therapy with, in chronic hepatitis B, 120:1828-srr resistance, in hepatitis B, 120:1000-srr, 120:1828-srr Leiomyomatosis, diffuse esophageal, 120:216-cr Ught-incluced fluorescence spectroscopy, 120:749 Ught-scattering spectroscopy, 120:749 Upids, duodenal, gastrointestinal sensations induced by, fat digestion and, 120:1071-tmig, 120:1100 Uver alcoholic disease of, risk of, homozygosity for alanine in mitochondrial targeting sequence of SOD and, 120:1318-tmig, 120:1468 alcoholic steatosis in, Kupffer cell and (rat), 120:581-ss alcohol-induced injury of, reduction of, by superoxide dismutase (rat), 120:1241 anatomy of, 120:1304-pmr arteriovenous malformations in, 120: 1579-im autoimmune injury of, mechanisms of, 120:1485-srr claudin expression and subcellular localization in, heterogeneity of (rat), 120:411 diseases of autoantibodies in, 120:239-srr chronic, and health-related quality of life, 120:170, 120:305-e diagnosis and management of, 120: 584-pmr HFE gene mutation analysis in, 120: 718 fibrosis in hepatitis C, response to interferon therapy, 120:579-ss Na+/H't exchanger and (rat), 120:545, 120:572-e prevention of, by protease inhibitor (rat), 120:1784 healthy, immunology of, 120:250-srr Helicobacter sp. in, 120:323-c organic anion-transporting polypeptides (OATPs) of, functional comparison of, 120:525

June 2001

retinoic acid metabolism, erhanol-induced CYP4502El and (rat), 120:179 sinusoidal bile acid uptake, impaired, in Amish kindred, 119:321-co

Liver/kidney microsome type 1, antibody to, in liver disease, 120: 239-srr

Liver transplantation for autoimmune hepatitis, 120:1502-srr contraindications to, 120:749 current status of, 120:749 historical perspective on, 120:749 indications for, 120:749 listing criteria for, 120:749 living donor, 120:749 novel approaches to, 120:749 organ shortage and, 120:749 recurrent disease after, 120:749 selection criteria for, 120:749 split, 120:749 xenotransplantation for, 120:749 Liver X receptors, and cholesterol and bile acid metabolism, 120:1054-ss Loperamide, in treatment of irritable bowel syndrome, 120:652 Lopinavir-ritonavir, therapy with, GI toxicity and GI-associated drug interactions of, 120:607

Lower esophageal sphincter (LES), vagal motor control of, site of action of GABAB receptor for, 120:1749 LST.2, and targeted chemotherapy for gastrointestinal cancer, 120: 1689 LWlg cancer, and Zollinger-Ellison syndrome, 120:1271-cr LWlg injury, after intestinal ischemiareperfusion, anti-C5 therapy and (rat), 120:126 Lymphoma, MALT, gastric, 120:1884-c

Lymphotoxin alpha (LTA), haplotype, and response to infliximab in Crohn's disease, 120:1347 and M cell development, in Peyer's patches (mouse), 120: 1173

Magnetic resonance imaging (MRI), in diagnosis of pancreatitis, 120:682 Magnification endoscopy, 120:749

Major histocompatibility complex (MHC), class I molecules, expression of, intestinal epithelial transport of bacterial peptides and, 120:1657

SUBJECT INDEX

Matrix meta1loproteinase (MMP), in inflammatory bowel disease, 120:622 M cells, mature lymphocyte-independent development of, in Peyer's patches (mouse), 120: 1173

Medicare HCFA policy and, 120:3-gn regularions, legislation aimed at reform of, and education on, 120:1320-gn Meloxicam, gastrointestinal events related to, risk of, 120:594

6-Mercaptopurine (6-MP) and azathioprine, for refractory microscopic colitis, 120:1483-cr for inflammatory bowel disease, 120:622 Mesalamine, for Crohn's disease, as maintenance therapy, 120:585-c Mesenteric vein, thrombosis anticoagulant therapy for, 120:578-ss increased levels of factor VIII:C as risk factor for, 120: 1563-c Metformin, prevention of pancreatic cancer induction (hamster), 120: lO72-tmig, 120:1263, 120:1291-e

Methotrexate for maintenance of remission in Crohn's disease, 120:1553-ss sensitivity, in gastrointestinal cancer, LST-2 and, 120:1689

N-Methyl-D-aspartate (NMDA) reo ceptors, peripheral, in visceral nociception (rat), 120: 1737

Methylprednisolone, for ulcerative coliris, comparison with unfractionated heparin, 120:1306-c, 120:1307-c MECA alleles, and primary sclerosing cholangiris, 120:1475 Ih-microglobu1in, somatic mutation of, and unfavorable prognosis in GI cancer of microsatellite mutator phenotype, 120:1565-c

Microsatellite instability

as prognostic indicator in chemotherapy for colorectal cancer, 120:1309-c screening for, in detection of hereditary nonpolyposis colorectal cancer, 120:1-tmig, 120:21

Microsatellite mutator phenotype, gastrointestinal cancer with, somatic mutation of ~r microglobulin gene and unfavorable prognosis in, 120:1565-c Migraine, abdominal, 120:263-aga Mitochondria, abnormalities of, and pathogenesis of nonalcoholic steatohepatitis, 120:1183, 120:1281-e

1919

Motilin-related peptide and ghrelin, 120:587-c, 120:588-c identification and characterization of, 120:587-c, 120:588-c

Mucosa gastric adaptive cytoprotection in, PGI 2 and CGRP in, 120:134 prostaglandin production in, COX-2 inhibitors and, 120:784-tmig, 120:867 gastrointestinal, in HIV-l infection, 120: 607

Mucosa-associated lymphoid tissue (MALT), gastric, lowgrade lymphoma of, 120:1884-c Mucosal immunity, HAART and, 120:984-cr

Multidrug resistance ~ gene (MDR3), defect and cholesterol cholelithiasis, 120:1459, 120:1549-e in progressive familial intrahepatic cholestasis type 3, 120:1448, 120: 1549-e Multiple sclerosis (MS), hepatitis B vaccine and, 120:1880-ss Muscular dystrophy, mdx mouse model of, mechanical tone of colon in, calcium influx and, 120: 1430 Mycophenolate, for autoimmune hepatiris, 120: 1502-srr

Nabumetone, gastrointestinal events related to, risk of, 120:594

Na+/H+ exchanger. See Sodium/hydrogen antiporter (sodium/hydrogen exchanger) Naproxen, gastrointestinal events related to, risk of, 120:594

Nausea and vomiting AGA medical position starement on, 120:261-aga AGA technical review on, 120:263-aga chemotherapy-related, 120:263-aga clinical approach to, 120:263-aga differential diagnosis of, 120:263-aga functional, 120:263-aga intractable, with gastroparesis, 120:263aga management of, 120:263-aga postoperative, 120:263-aga radiation-related, 120:263-aga socioeconomic effects of, 120:263-aga Near-infrared imaging, 120:749 Nelfinavir, GI toxicity and GI-associated drug interactions of, 120:607 Neurotensin, and jejunal bile acid absorption (rat), 120:151

1920 SUBJECT INDEX

Nevirapine, G1 toxiciry and G1-associated drug interactions of, 120:607 Nitric oxide, and oxidative DNA damage in cholangiocytes, 120:190 Nitric oxide synthase (NOS), inducible, stimulation by NF-KB, and protection against TNF-a and Fas-mediated apoptosis in hepatocytes (mouse), 120:1251 Nodception, visceral, peripheral NMDA receptotS in (tat), 120: 1737 Nonalcoholic steatohepatitis, insulin resistance and mitochondtial abnormalities in, 120:1183, 120: 1281-e

Non-nucleoside reverse transcriptase inhibitors, G1 toxicity and G1-associated drug interactions of, 120:607

Nonsteroidal anti-inflammatory drugs (NSAIDs) gastrointestinal events related to tisk factots fot, 120:594 strategies for decreasing, 120:594 and Helicobacter pylori, 120:594 inflammation induced by, vascular anatomy in, 120:1885-c use in high-risk patients, 120:594 Norvir. See Ritonavir Nuclear factor KB, activation of by Cryptosporidium parvum, in biliary epithelia, and prevention of epithelial cell apoptosis, 120:1774 and iNOS, in TNF-a and Fas-mediated apoptosis in hepatocytes (mouse), 120:1251 Nuclear receptors, orphan, and cholesterol and bile acid metabolism, 120: 1054-ss

Nucleoside analogs G1 toxicity and G1-associated drug interactions of, 120:607 therapy with, for hepatitis B, 120:1828srt

Nucleoside reverse transcriptase inhibitors, G1 toxicity and G1-associated drug interactions of, 120:607

Nutrition advances in (future directions for), 120: 1319-gn in short-bowel syndrome, GLP-2 administration and, 120:783-tmig, 120:806, 120:1041-e

Obesity classification of, 120:669 comorbidities in, 120:669 and insulin resistance, in pancreatic carcinogenesis, 120:1072-tmig, 120:1263, 120:1291-e

GASTROENTEROLOGY Vol. 120, No.7

management of, advances in (future directions for), 120:1319-gn medical therapy for, 120:669 surgical therapy for, 120:669 Obstetrics, hepatitis C and, 120: 15 55-ss

Odreotide for acute variceal bleeding, meta-analysis of, 120:946 effects on porral hypertension, 120:2tmig, 120:161, 120:303-e effects on porral hypertension (rat), 120: 975 Omepraxole, and nonacid GERD, 120: 1599 Oncology, clinical, 120:583-pmr

Optical coherence tomography,

120:749 in diagnosis of specialized intestinal metaplasia, 120:1-tmig, 120:7

Organic anion-transporting polypeptide B (OATP-B), functional comparison with other OATPs of human liver, 120:525

Organic anion-transporting polypeptides, expression cloning and functional tests of, 120:1887-c Orlistat, for obesity, 120:669 Oxidants, and C1- secretion in intestinal epithelial T84 cells, 120:2-tmig, 120:89 Oxidative stress, and pathogenesis of nonalcoholic steatohepatitis, 120: 1183, 120:1281-e

Pacemakers, intestinal, organization of, 120:319-co Pain, visceral, peripheral NMDA receptors in (rat), 120:1737

Pancreas claudin expression and subcellular localization in, heterogeneity of (rat), 120:411 structural imaging of, in diagnosis of pancreatitis, 120:682 Pancreatic acinar cells, digestive enzyme secretion by, apical actin and, 120:1818

Pancreatic cancer association with obesity and insulin resistance, 120:1072-tmig, 120:1263, 120:1291-e induction of, prevention of, by metformin (hamster), 120:1072tmig, 120:1263, 120:1291-e SST2 gene polymorphism and, 120:200

Pancreatic secretory trypsin inhibitor gene mutations, in idiopathic chronic pancreatitis, 120:1061-c

mutations, and chronic pancreatitis, 120: 682

Pancreatitis acute initial episode of, evaluation during, 120:708 recurrent, 120:682 causes of, 120:708 inciting factors, identification and elimination of, 120:708 severe, 120:682 chronic autoimmune, 120:682 classification of, 120:682 clinical manifestations of, 120:682 diagnosis of, 120:682, 120:708 epidemiology of, 120:682 etiology of, 120:682 genetic predispositions to, 120:682 idiopathic, 120:682 PTS1 gene mutations in, 120:1061-c minimum change, 120:682 obstructive, 120:682 risk factors for, 120:682 SPINK] mutations in, 120:1060-c staging of, 120:682 tropical, 120:682 ERCP-induced, protection against, by 1L-lO, 120:332-tmig, 120:498

Paracentesis for ascites, rationale for, 120:726 for refractory ascites, 120:311-ss, 120: 726

Pediatrics acute diarrhea in, management of, 120: 783-tmig, 120:799 1BS in, 120:1-tmig, 120:31, 120:287-e

Peroxisome proliferator activator receptor(s) (PPAR), PPAR-y, and anti-inflammatory activity in ischemia-reperfusion injury (mouse), 120:332-tmig, 120:460 pS~

gene

and hepatocarcinogenesis, 120:1763 in ulcerative colitis, and cancer, 120: 1877-ss Pheochromocytoma, radiologic appearance of, 120:6-im

Phosphatidylinositol 3-kinase bile acid-activated pathway, inhibition of Fas-mediated apoptosis in rodent hepatocytes, 120:1810 and HT29 and Caco-2 intestinal cell differentiation, 120: 131 7-tmig, 120:1381, 120:1543-e and TNF-a-induced COX-2 expression in colonic epithelial cells, 120: 1117

June 2001

Phospholipase Az (PLAz ), and cholesterol absorption (mouse), 120: 1193 Photodynamic diagnosis, 120:749

Photodynamic therapy for Barrett's esophagus, persistent genetic abnormalities after, 120:1064-c, 120:1065-c in Barrett's esophagus, 120:785-gn Piroldcam, gastrointestinal events related to, risk of, 120:594 p27Kipl, in human intestinal cell differentiation, 120:423

Politics and publishing Bush administration and gastroenterology, 120:333-gn FDA seeks to increase access to information on xenotransplantation, gene therapy trials, 120:786-gn and Medicare regulations, 120:1320-gn and student loan burden, 120:1320-gn Polyps, colorectal, transition to colorectal carcinoma, APC gene I1307K mutation and, 120:331-tmig, 120:392

Portal hypertension complications of, current management of, 120:726 effects of octreotide on, 120:2-tmig, 120:161, 120:303-e effects of octreotide on (rat), 120:975 Portal vein, thrombosis anticoagulant therapy for, 120:490, 120: 578-ss increased levels of factor VIII:C as risk factor for, 120:1563-c Potassium channels, KCNQ1, in gastric acid secretion, 120: 1363 Powell, Don W., presentation of Julius M. Friedenwald Medal to, 120: 1854-aga Prebiotic therapy, in inflammatory bowel disease, 120:622 Preveon. See Adefovir dipivoxil

Primary sclerosing cholangitis,

MICA polymorphism in, 120: 1475 Primum non nocere, postapproval drug surveillance and, 120:5-ce Print and Media Reviews Atlas of Gastrointestinal Endoscopy & Endoscopic Biopsies, 120: 1304 Atlas of the Liver, 120:1304 Development of the Gastrointestinal Tract, 120:1883 Evidence Based Gastroenterology and Hepatology, 120:1559 Fast Facts: I"itable Bowel Syndrome, 120: 1559 Gastroesophageal Reflux Disease, 120:583 Gastrointestinal Motility, 120:1056

SUBJECT INDEX

Inflammatory Bowel Disease: Clinical Diagnosis and Management, 120:1057 Inner Hygiene: Constipation and the Pursuit of Health in Modern Society., 120:317 Liver Disease: Diagnosis and Management, 120:584 My Mom Has Hepatitis C, 120:1056 Positive Options for Crohn'J DiJease, SelfHelp and Treatment., 120:317 Selected TopicJ in Clinical Oncology, 120: 583 Probiotic therapy, in inflammatory bowel disease, 120:622, 120: 1297-ss

Proctitis/proctocolitis of infancy, dietary protein-induced, 120: 1026-aga

Progressive familial intrahepatic cholestasis type 3, multidtug resistance 3 gene (MDR3) defect in, 120:1448, 120:1549-e

Prokinetic agents and bacterial translocation in cirrhosis, 120:314-ss for nausea and vomiting, 120:263-aga Proleukin. See Interleukin(s), IL-2 Propranolol, and bacterial translocation in cirrhosis (rat), 120:314-ss Prostacydin (PGl z), and adaptive cytoprotection in gastric mucosa, 120:134 Prostaglandins, gastric mucosal production of, COX-2 inhibitors and, 120:784-tmig, 120:867 Protease, serine 1 (PRSS1). See Trypsinogen, cationic

Protease inhibitor GI toxicity and GI-associated drug interactions of, 120:607 in prevention of hepatic fibrosis (rat), 120:1784 Protectin, Helicobacter pylori bound to, protection from complement lysis, 120:332-tmig, 120:470 Protein kinase C (PKC), PKC-8, and colon carcinogenesis, 120:1700, 120:1868-e Prothrombin gene, G20210A mutation, and portal or hepatic venous thrombosis, 120:1059-c Proton pump, as target autoantigen of Thl-type cytotoxic T cells in autoimmune gastritis, 120:377 Prucaloprid.e, for functional constipation, 120:331-tmig, 120:354 Psychotropic agents, in treatment of irritable bowel syndrome, 120: 652

Public policy Bush administration and gastroenterology, 120:333-gn

1921

HCFA policy hurrs gastroenterologists and Medicare patients, AGA charges, 120:3-gn

Racecadotril, in acute diarrhea in children, efficacy and tolerability of, 120:783-tmig, 120:799 :a..u.ation therapy, nausea and vomiting caused by, 120:263-aga Raman spectroscopy, 120:749

Rapid Co......unications

Germline variants of EXOI gene in patients with atypical hereditary nonpolyposis colorectal cancer, 120:1580 Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin, 120:337

Rectum hypersensitivity, in childhood, 120:31, 120:287-e primary squamous cell carcinoma of, HPV type 16 and, 120:988-cr, 120:1046-e Rehydration therapy, in acute diarrhea in children, 120:783-tmig, 120:799 Reimbursement, HCFA policy and, 120:3-gn Renal failure, chronic, and chronic pancreatitis, 120:682 Rescriptor. See Delavirdine

Research funding for in Germany, 120:334-gn in Japan, 120:1074-gn on gene therapy, public access to, 120: 786-gn on xenotransplantation, public access to, 120:786-gn Retinoblastoma pathway, in colonic adenomas, 120:1680 Retinoic add, metabolism, ethanolinduced CYF4502El and (rat), 120:179 Retinoid X receptor, and cholesterol and bile acid metabolism, 120: 1054-ss Retrovir. See Zidovudine Ritonavir, GI toxicity and GI-associated drug interactions of, 120:607 RofecoJdb, and human gastric mucosal prostaglandin production, 120: 784-tmig, 120:867 Roldtansky, Karl von, 120:1598

SIll.....". aortitis, 120:1322-im Salsalate, gastrointestinal events related to, risk of, 120:594

Santorini, Giovanni Domenico, 120:805

1922

SUBJECT INDEX

Saquiaa'rir, GI toxicity and GI-associated drug interactions of, 120: 607

Selected Summaries Alcoholic steatosis: the Kupffer cell a villain?, 120:581 Are things looking up for the treatment of gastroparesis? Sildenafil in animal models of diabetic gastropathy, 120:576 Bile acids regulate their own synthesis: the nuclear connection, 120: 15 57 Cesarean for C? Possibly..., 120:1555 He/icobacter eradication versus prompt endoscopy for dyspepsia, 120:1298 The hepatitis B vaccine: sorting through the B.S. about M.S., 120:1880 Is hepatic fibrosis reversible with therapy in hepatitis C?, 120:579 Management of gastric varices, 120:1875 Management of refractory ascites: are TIPS or taps tops?, 120:311 Manipulating intestinal cholesterol absorption and hepatic cholesterol and bile acid metabolism by activation of deorphanized nucleat receptors, 120:1054 Methotrexate fot the maintenance of remission in Crohn's disease, 120: 1553 Novel medical therapies for Crohn's disease: is there room for growrh?, 120:308 Nurritional therapy for alcoholic hepatitis: new life for an old idea, 120: 1053 p53 at the crossroads of colitis and cancer, 120:1877 Predicting the ourcome of hepatitis C virus infection, 120:312 The prevention of hepatocellular carcinoma by interferon: the story continues, 120:1301 Prokinetics reduce bacterial translocation in cirrhosis: will sweeping the gut keep the fluid clean?, 120: 314 The road not taken, 120:1878 Single-stage operations for Hirschsprung's disease - pushing the envelope, 120:1299 Tteatment of hepatoportal venous thrombosis: the role of anticoagulation, 120:578 Turbo probiotics for IBD, 120:1297 What lies beyond the view of the sigmoidoscope?,120:1051 What's right and what's left?, 120:1049 Seledins, differential role of, in experimental colitis, 120:1072-tmig, 120:1162

GASTROENTEROLOGY Vol. 120, No.7

Seledive serotonin reuptake inhibitors (SSRIs), in treatment of irritable bowel syndrome, 120:652 Sepsis, hepatobiliary dysfunction in, protective role of carbon monoxide from heme catabolism in (rat), 120:1227, 120:1288-e Serine protease, and digestive enzyme secretion in pancreatic acinar cells, 120:1818

Serine protease inhibitor, Kual type 1 (SPINKl). See a/so Pancreatic secretory trypsin inhibitor gene mutations, in chronic pancreatitis, 120:1060-c Short-bowel syndrome, treatment of, glucagon-like peptide 2 in, 120: 783-tmig, 120:806, 120:1041-e Sibutramine, for obesity, 120:669 Sigmoidoscopy, limitations of, 120: 1049-ss, 120:1051-ss Sildenafil, therapy with, in animal models of diabetic gastropathy, 120: 576-ss

Small intestine

claudin expression and subcellular localization in, heterogeneity of (rat), 120:411 motility, GRP receptor blockade and, 120:331-tmig, 120:361 muscle in, tachykinin receptor NK 1 on, immunohistochemical demonstration of (guinea pig), 120:1140 Smoking, and chronic pancrearitis, 120: 682 Smoking cessation, and course of Crohn's disease, 120:1071-tmig, 120:1093 Smooth muscle, enteric, persistent postinfective dysfunction, immunologic factors and COX-2 in (mouse), 120:1713 Smooth muscle antibody, in liver disease, 120:239-srr Smooth muscle relaxants, in treatment of irritable bowel syndrome, 120:652

Sodium/hydrogen antiporter (sodium/hydrogen exchanger) and hepatic fibrosis (rat), 120:545, 120: 572-e and hepatic stellate cell activation (rat), 120:545, 120:572-e Somatostatin receptor gene, polymorphism, in human pancreatic cancer cells, 120:200

Spedal Reports and Reviews Acute flares in chronic hepatitis B: the

natural and unnatural history of an immunologically mediated liver disease, 120: 1009 Autoantibodies in liver disease, 120:239 Auroimmune hepatitis: clinical challenges, 120:1502 Chromosomal organization of candidate genes involved in cholesterol gallstone formation: a murine gallstone map, 120:221 Immunology of the healthy liver: old questions and new insights, 120: 250 The lymphoid liver: considerations on pathways to auroimmune injury, 120:1485 Management of hepatitis B: 2000-summary of a workshop, 120:1828 Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection, 120: 1000 Spectroscopy, for evaluation of dysplasia in Barrett's esophagus, 120: 1607 Splenic vein, thrombosis, increased levels of factor VIII:C as risk factor for, 120:1563-c

Spontaneous bacterial peritonitis acute, treatment of, 120:726 current management of, 120:726 primary prophylaxis for, 120:726 recurrent, prevention of, 120:726 Squamous cell cardnoma, primary rectal, HPV type 16 and, 120: 988-cr, 120:1046-e Stavudine, GI toxicity and GI-associated drug interactions of, 120:607 Stellate cells, hepatic activation of, Na+/H+ exchanger and (rat), 120:545, 120:572-e apoptosis in, peripheral-type benzodiazepine receptor expression and, 120:1212, 120:1285-e Stensen, Niels, 120:38 Steroids, for ulcerative colitis, comparison with unfractionated heparin, 120:1306-c, 120:1307-c

Stimulator of Fe transport (SF1'), duodenal expression of, in anemia and hemochromatosis, 120:1404

Stomach claudin expression and subcellular localization in, heterogeneity of (rat), 120:411 human antral gastrin cells, calcium-sensing receptor in, mechanism of action of, 120:1128, 120:1279-e low-grade MALT lymphoma of, 120: 1884-c

SUBJECT INDEX 1923

June 2001

stress, and induction of EGF-Iike growth factors in gastric epithelial cells (rat), 120:108

Student Loan Interest Dedud:ion Act, 120:1320-gn Sucra.e-i.-omaltase, as epithelial cAMP-dependent chloride channel, 120:117, 120:299-e Supero:dde dismatue mitochondrial targeting sequence of, homozygosiry for alanine in, and risk for alcoholic liver disease, 120:1318-tmig, 120:1468 and reduction of alcohol-induced liver injury (rat), 120:1241 Sustiva. See Efavirenz

Tachyldnin receptor, NK 1 , immunohistochemical demonstration of, on intestinal muscle and epithelia (guinea pig), 120:1140

Tachyldnins and nerve-mediated contractions in human esophagus, 120:1-rmig, 120:39 and peristalsis in isolated distal colon (guinea pig), 120:938 TacroUmus, fot autoimmune hepatitis, 120:1502-5rr TartikofJ, Lily, and CRC screening, 120:333-gn 3TC. See Lamivudine T cells (T lymphocytes) CD4+ of lamina propria, HIV-1 infection and, 120:607 mucosal, HAART-related increase in, 120:984-cr CD8+, apoptosis, in liver, 120:250-5rr and colitis, in Tge26 mice, 120:900 development of, in liver, 120:250-5rr Thl-rype cytotoxic, H+,K+-ATPasespecific, in autoimmune gastritis, 120:377 Telangiectasia, bleeding, of gastrointestinal tract, abnormal von Willebrand factor in, 120:346 ThaHdomide therapy, cessation of, intractable insomnia after, 120:

1567-c This Month in GASTROENTEROLOGY Acute diarrhea in children: is rehydration therapy enough?, 120:783 APe 1307K and the risk of colorectal cancer, 120:331 Can baseline adenoma characteristics predict the recurrence of advanced adenomas?, 120:1071 Cereal fiber may reduce the risk of gastric cardia cancer, 120:331

Colonic luminal contents induce cydooxygenase 2 rranscription, 120:332 COX-2 inhibits spare gastroprotective prostaglandins, 120:784 Do genes determine susceptibiliry to alcoholic liver disease?, 120:1318 Effect of duodenal iron absorption on iron homeostasis, 120: 1317 Effects of octreotide on portal hypertension, 120:2 Endogenous PPAR'Y mediates inflammation in ischemia-tepecfusion injury, 120:332 Esophageal manometry for the diagnosis of achalasia, 120:783 Family history of colorectal cancer may increase IBD-associated CRC, 120:1317 Fat digestion modulates gastrointestinal symptoms, 120:1071 Glucagon-like peptide 2 administration for the treatment of short-bowel syndrome, 120:783 Hepatitis C viral kinetics and peginterferon a2a, 120:1318 Human papilloma virus and the risk of anal canal cancer, 120:784 IBD and the risk for colorectal cancer, 120:783 Interleukin 10 reduces postherapeutic ERCP-induced pancreatitis, 120: 332 Irritable bowel syndrome in children, 120:1 Localization of mutant Wilson disease protein, 120:784 Mechanisms for gastrointestinal motility, 120:331 Microsatellite instabiliry and genetic testing for HNPCC, 120:1 New tteatment modalities for inflammatory bowel disease, 120:1317 Optical coherence tomography in the diagnosis of specialized intestinal metaplasia, 120:1 Oxidants potentiate agonist-induced Clsecretion in intestinal epithelial T84 cells, 120:2 Pancreatic cancer and obesiry, 120:1072 Phosphatidylinositol 3-kinase and intestinal differentiation, 120: 1317 Predictots for relapse in ulcerative colitis, 120:1 Prognostic value of measuring circulating colotectal cancer cells, 120:1071 Protectin-bound H. pylori prevents complement-induced lysis, 120:332 Prucalopride for the treatment of functional constipation, 120:331

Role of rachykinins in nerve-mediated contractions in the human esophagus, 120:1 Selectins in experimental colitis, 120: 1072 Smoking cessation and Crohn's disease, 120:1071

ThronabophDic: gene mutations, and portal or hepatic venous thrombosis, 120:1059-c Time-resolved fluorescence, 120: 749 ToJdns, and chronic pancreatitis, 120:682 Toxoplasmosis, ileitis after, regulation by TGF-~-producing intraepitheIiallymphocytes (mouse), 120: 914 TransepitheUal sign-UnC, in human stomach, 120:1128, 120:1279-e Transferrin receptor, duodenal expression of, in anemia and hemochromatosis, 120:1404

TransforminC growth factor

~

(TGF-P) in hepatic fibrosis (tat), 120:1784 and regulation of ileitis after intracellular parasite infection (mouse), 120: 914

Transgenic: mice cell-specific targeting of genes in, keratin 19 promoter for, 120:1728 keratin 19, 120:1728

Transjugular intrahepatic: portosystemic: shunt (npS), for refractory ascites, 120:311-5s

Trypsinogen, cationic, gene mutations, and chronic pancreatitis, 120:682

Tuberadosis, ileocecal, 120:1076-im Tumor necrosis factor, engineered human antibody to (CDP571), for active Crohn's disease, 120: 1317-tmig,120:1330

Ulcerative colitis (UC) backwash ileitis in, and colorectal cancer risk, 120:783-tmig, 120:841 p53 gene in, and cancer, 120:1877-55 refractory, laparoscopic appendectomy with, 120:1562-c relapse in, predictors of, 120:1-tmig, 120:13 treatment of, IV cydosporine versus IV corticosteroids as single therapy for, 120:1317-tmig, 120:1323, 120:1541-e Ulcerative enteritis, in celiac disease, 120:1526--aga Unodiol, and impaired liver sinusoidal bile acid uptake in Amish kindred, 119:321-co

1924

GASTROENTEROLOGY Vol. 120, No.7

SUBJECT INDEX

v.... fterYe, and motot control of lower esophageal sphincter, GABAB receptors in, 120:1749

Variceal b1eedhaa acute octreotide for, meta-analysis of, 120: 946 treatment of, 120:726 endoscopic sclerotherapy for, complications of, 120:336-im first episode of, prevention of, 120:726 gastric, management of, 120:1875-ss recurrent, prevention of, 120:726 Varices, prevention of, 120:726 Vuocoastric:tiOft, PKC-dependent, in portal hypertension, octreotide and (rat), 120:975 VideL See Didanosine Viracept. See Nelfinavir

Viraaaae. See Nevirapine Vomitiaa. See a/so Nausea and vomiting cyclic, 120:263-aga YO. llippel-Liaclau (VRL) disease, 120:788-im YOft Willebraad fiKtor, abnormalities of, in gastrointestinal bleeding angiodysplasias, 120:346

""'h, Joha, 120:335-ce

wnso. disa.e, ATP7B protein mutants in localization of, 120:784-tmig, 120:967 properties of, 120:784-tmig, 120:967 X c:hroaaOS08le, in8ammatory bowel disease susceptibility locus on, 120:834

Xeaotrlulsplaatatioft information on, FDA seeks to increase access to, 120:786-gn of liver, 120:749

ZalciUlbiae, GI toxiciry and GI-associated drug interactions of, 120:607

ZDV. See Zidovudine ZDV-3TC, GI toxicity and GI-associated drug interactions of, 120:607

Ziagea. See Abacavir Zidovudiae, GI toxicity and GI-associated drug interactions of, 120: 607

Zolliaaer-EIIisoft syadrome, lung cancer and, 120:1271-cr